Sotera Health (NASDAQ:SHC) Receives $16.50 Consensus Price Target from Analysts

Shares of Sotera Health (NASDAQ:SHC) have received an average recommendation of “Moderate Buy” from the six research firms that are currently covering the stock, MarketBeat.com reports. Two equities research analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $16.50.

SHC has been the subject of a number of recent analyst reports. Citigroup raised their price objective on shares of Sotera Health from $18.00 to $20.00 and gave the stock a “buy” rating in a research note on Wednesday, November 6th. Royal Bank of Canada reiterated an “outperform” rating and issued a $17.00 target price on shares of Sotera Health in a research note on Tuesday, August 6th. Finally, Barclays increased their price objective on Sotera Health from $14.00 to $17.00 and gave the company an “overweight” rating in a report on Tuesday, August 6th.

Sotera Health Stock Performance

SHC opened at $13.21 on Thursday. The business has a 50 day moving average price of $15.77 and a two-hundred day moving average price of $13.94. The company has a debt-to-equity ratio of 4.91, a current ratio of 2.88 and a quick ratio of 2.61. The company has a market capitalization of $3.74 billion, a price-to-earnings ratio of 52.84 and a beta of 2.08. Sotera Health has a 1-year low of $10.71 and a 1-year high of $17.44.

Sotera Health (NASDAQ:SHC) last released its earnings results on Tuesday, November 5th. The company reported $0.17 EPS for the quarter, missing the consensus estimate of $0.18 by ($0.01). Sotera Health had a net margin of 6.31% and a return on equity of 42.27%. The business had revenue of $285.47 million for the quarter, compared to analyst estimates of $278.64 million. During the same period in the prior year, the company earned $0.18 earnings per share. The firm’s revenue for the quarter was up 8.5% on a year-over-year basis. Research analysts predict that Sotera Health will post 0.61 EPS for the current fiscal year.

Insider Transactions at Sotera Health

In other news, Director Gtcr Investment Xi Llc sold 10,000,000 shares of the stock in a transaction that occurred on Friday, September 6th. The stock was sold at an average price of $15.03, for a total value of $150,300,000.00. Following the completion of the transaction, the director now directly owns 49,215,301 shares of the company’s stock, valued at approximately $739,705,974.03. This represents a 16.89 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. 55.12% of the stock is owned by insiders.

Institutional Trading of Sotera Health

Large investors have recently bought and sold shares of the stock. CWM LLC raised its stake in shares of Sotera Health by 86.1% in the second quarter. CWM LLC now owns 2,146 shares of the company’s stock worth $25,000 after acquiring an additional 993 shares during the last quarter. True Wealth Design LLC acquired a new stake in shares of Sotera Health during the 3rd quarter worth approximately $32,000. GAMMA Investing LLC raised its stake in shares of Sotera Health by 125.0% during the third quarter. GAMMA Investing LLC now owns 2,988 shares of the company’s stock worth $50,000 after buying an additional 1,660 shares during the last quarter. Point72 DIFC Ltd boosted its stake in Sotera Health by 556.6% in the second quarter. Point72 DIFC Ltd now owns 6,540 shares of the company’s stock valued at $78,000 after acquiring an additional 5,544 shares during the last quarter. Finally, Capital Performance Advisors LLP bought a new position in shares of Sotera Health in the 3rd quarter worth $91,000. 91.03% of the stock is currently owned by institutional investors.

Sotera Health Company Profile

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.